Granted Patent
B2
US 8,518,905 · App. 13/461,672 · Granted Aug 27, 2013
Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
Claims (2)
1. A method of reducing the risk of an infant developing necrotizing enterocolitis comprising administering, to the infant, an effective amount of a TLR9 agonist.
2. The method of claim 1 , wherein the TLR9 agonist is an oligonucleotide comprising an unmethylated CpG dinucleotide.
Assignments (2)
CONFIRMATORY LICENSE
Recorded May 24, 2012
From: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028274/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 1, 2012
From: HACKAM, DAVID J.; GRIBAR, STEVEN C.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 028138/0731 →
Continuity (4)
Provisional Application
60912862
· Apr 19, 2007
Provisional Application
61027728
· Feb 11, 2008